National Center for Scientific Research Demokritos, Athens, Greece.
Department of Pathology, University of Massachusetts Medical School, Worcester, MA, USA.
Mol Immunol. 2019 Sep;113:50-57. doi: 10.1016/j.molimm.2018.03.026. Epub 2018 Apr 17.
Endoplasmic Reticulum aminopeptidase 1 (ERAP1) is an intracellular enzyme that can generate or destroy potential peptide ligands for MHC class I molecules. ERAP1 activity influences the cell-surface immunopeptidome and epitope immunodominance patterns but in complex and poorly understood manners. Two main distinct pathways have been proposed to account for ERAP1's effects on the nature and quantity of MHCI-bound peptides: i) ERAP1 trims peptides in solution, generating the correct length for binding to MHCI or overtrimming peptides so that they are too short to bind, and ii) ERAP1 trims peptides while they are partially bound onto MHCI in manner that leaves the peptide amino terminus accessible. For both pathways, once an appropriate length peptide is generated it could bind conventionally to MHCI, competing with further trimming by ERAP1. The two pathways, although not necessarily mutually exclusive, provide distinct vantage points for understanding of the rules behind the generation of the immunopeptidome. Resolution of the mechanistic details of ERAP1-mediated antigenic peptide generation can have important consequences for pharmacological efforts to regulate the immunopeptidome for therapeutic applications, and for understanding association of ERAP1 alleles with susceptibility to autoimmune disease and cancer. We review current evidence in support of these two pathways and discuss their relative importance and potential complementarity.
内质网氨肽酶 1(ERAP1)是一种细胞内酶,能够产生或破坏 MHC Ⅰ类分子的潜在肽配体。ERAP1 的活性影响细胞表面免疫肽组和表位免疫优势模式,但方式复杂且理解不足。为了解释 ERAP1 对 MHCⅠ结合肽的性质和数量的影响,提出了两种主要的不同途径:i)ERAP1 在溶液中修剪肽,生成与 MHCⅠ结合的正确长度或过度修剪肽,使它们太短而无法结合;ii)ERAP1 以肽氨基末端可及的方式在部分结合到 MHCⅠ上时修剪肽。对于这两种途径,一旦生成适当长度的肽,它就可以常规地与 MHCⅠ结合,与 ERAP1 的进一步修剪竞争。这两种途径虽然不一定相互排斥,但为理解免疫肽组生成背后的规则提供了不同的视角。解决 ERAP1 介导的抗原肽生成的机制细节,对于为治疗应用调节免疫肽组的药物学努力以及理解 ERAP1 等位基因与自身免疫性疾病和癌症易感性的关联具有重要意义。我们回顾了支持这两种途径的现有证据,并讨论了它们的相对重要性和潜在互补性。